A new multi-site study led by researchers at CU Anschutz shows that people with cystic fibrosis (CF) who start the triple-drug therapy elexacaftor/tezacaftor/ivacaftor (ETI) can safely reduce many of their daily lung treatments while maintaining good health for years.
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
A financial report on Colorado hospitals said that they are far from triumphing over pandemic-era challenges. Click here to view original post
The takeaway: Click here to view original post Click Here to Publish/Feature Your Company or Product News with Biotech Networks
BOULDER, Colo., Nov. 13, 2023 /PRNewswire/ — In an era of artificial intelligence (AI) and machine learning (ML), quantitative magnetic resonance imaging (qMRI) is improving medical imaging and the standard of care. CaliberMRI, an industry […]
Copyright © 2026 Biotech Networks
